BioSpace News Archive

Conference Call to be held Thursday, August 13, 2020 at 5:00 pm EDT

Quantzig, a premier analytics solutions provider, launched a comprehensive portfolio of clinical data analytics solutions as part of the company’s commitment to transform the way pharma, biopharma, and life sciences companies access market and business intelligence services for their strategic needs.

Avrio Health L.P., a subsidiary of Purdue Pharma L.P. (“Purdue”), is reporting encouraging preliminary results of an in vitro (laboratory) study assessing Betadine® Antiseptic Sore Throat Gargle

Subtle Medical is approved for Phase II of its NIH SBIR grant to develop an innovative artificial intelligence (AI)-powered software, SubtleGAD™, which uses deep learning (DL) to reduce gadolinium dosage needed during MRI exams.

AllStar Health Brands Inc. a specialty pharmaceutical and nutritional supplements company and TPT Global Tech a technology and solutions company are pleased to announce signing a distribution agreement for Mexico and other Latin American countries through TPT Global Tech’s partner New Orbit Technologies.

Premier Medical Laboratory Services (PMLS) announces today that they have been named one of the Top Genetic Diagnostic Companies of 2020 by Healthcare Tech Outlook, a leading national healthcare publication.

Acer Therapeutics Inc. (Nasdaq: ACER), a pharmaceutical company focused on the acquisition, development and commercialization of therapies for serious rare and life-threatening diseases with significant unmet medical needs, today reported financial results for the second quarter ended June 30, 2020,

CohBar, Inc. (NASDAQ: CWBR), a clinical stage biotechnology company developing mitochondria based therapeutics to treat chronic diseases and extend healthy lifespan, today reported its financial results for the second quarter ended June 30, 2020.

NeuBase Therapeutics, Inc. (Nasdaq: NBSE) (“NeuBase” or the “Company”), a biotechnology company developing next-generation antisense oligonucleotide (ASO) therapies using its scalable PATrOL™ platform to address genetic diseases, today reported its financial results for the three and nine month periods ended June 30, 2020

Histogen Inc. (NASDAQ: HSTO), a clinical-stage therapeutics company focused on developing potential first-in-class restorative therapeutics that ignite the body’s natural process to repair and maintain healthy biological function, today reported financial results for the second quarter ended June 30, 2020 a